AXIOM INVESTORS

QUARTERLY STRATEGY FACTSHEET

AS OF SEPTEMBER 30, 2026

Emerging Markets Equity *Strategy*

Capitalizing on change through high-quality *dynamic growth investing*

INCEPTION	FIRM ASSETS	STRATEGY ASSETS	BENCHMARK
Aug 1, 2007	$34.8B*	$4.4B	MSCI EM (Net)

WHY INVEST?

A consistent, time-tested philosophy
Dynamic growth, capitalizing on change since 1998, buy and monitor.


Aligned, independent ownership
Partner-led stewardship, co-investment alongside clients.

Disciplined, conviction-weighted
Rigorous risk/return framework, disciplined conviction-weighted sizing.

Seasoned team, evidence-driven
30+ years PM experience, Axware amplifies alpha edge.

ANNUALIZED RETURNS · %


As of 9/30/2026 · USD · Periods over one year annualized



Past performance is not indicative of future results, and the principal value and investment return will fluctuate, so that you may have a gain or loss when you sell your units.

CUMULATIVE RETURNS · %

Since inception 8/1/2007 · As of 9/30/2026 · USD



*Assets include Assets Under Management ($33.2B) & Assets Under Advisement ($1.6B). **SEI Trust Company (the "Trustee") serves as the Trustee of the Trust and maintains ultimate fiduciary authority over the management of, and the investments made in, the Fund. The Fund is part of a Collective Investment Trust (the "Trust") operated by the Trustee. The Trustee is a trust company organized under the laws of the Commonwealth of Pennsylvania and a wholly owned subsidiary of SEI Investments Company (SEI). Axiom CIT Trusts are trusts for the collective investment of assets of participating tax qualified pension and profit sharing plans and related trusts, and governmental plans as more fully described in the Declaration of Trust. As bank collective trusts, the Axiom CIT Trusts are exempt from registration as an investment company. Axiom CIT Trusts are managed by SEI Trust Company, the trustee, based on the investment advice of Axiom Investors, LLC, the investment adviser to the trusts. Source: Factset and Axiom. There can be no assurance that the Strategy will continue to hold these positions or that weightings do not change after the as of date stated. Please refer to the attached GIPS compliant presentation for complete performance information. FOR PLAN SPONSOR USE ONLY.

Portfolio *characteristics*

Representative account vs. MSCI EM (Net) · As of 9/30/2026

TOP 10 HOLDINGS


HOLDING	COUNTRY	SECTOR	AXIOM (%)	INDEX (%)
Taiwan Semiconductor	Taiwan	Info Tech	16.9	15.6
Samsung Electronics	Korea	Info Tech	8.9	8.5
SK hynix	Korea	Info Tech	6.7	5.9
MediaTek	Taiwan	Info Tech	2.6	1.8
WuXi AppTec	China	Health Care	2.3	0.1
Embraer	Brazil	Industrials	2.2	0.1
China Construction Bank	China	Financials	2.2	0.9
ASPEED Technology	Taiwan	Info Tech	2.1	0.2
Alibaba Group	China	Cons Disc	1.7	1.9
Tencent Holdings	China	Comm Services	1.5	2.7

CHARACTERISTICS

	AXIOM	INDEX
Number of holdings	82	1,165
Weight in top 10 holdings	47.2%	37.7%
Wtd. avg. market cap ($B)	$576.6	$539.6
Median market cap ($B)	$31.2	$12.2
Liquidity ($M / day)	$1,338.3	$1,199.9
Net debt / equity	−6.8	−3.6
P/E ratio (forward)	10.6	9.6
Earnings growth (forward)	39.7	34.1
PEG ratio	0.3	0.3

SECTOR EXPOSURE


% of portfolio



Information Technology	48.3
Financials	18.1
Industrials	14.4
Consumer Discretionary	5.3
Health Care	4.0
Communication Services	3.6
Materials	2.3
Consumer Staples	1.8
Energy	0.9
Real Estate	0.7

REGIONAL EXPOSURE

% of portfolio



Asia ex Japan	80.2
Latin America	9.4
EMEA	7.5
Europe ex UK	2.3

PORTFOLIO MANAGERS

José Gerardo Morales, CFA
LEAD PORTFOLIO MANAGER

Andrew Jacobson, CFA
CIO/PORTFOLIO MANAGER

Alexander Harrison
PORTFOLIO MANAGER

Currency: USD. Source: Factset and Axiom. Past performance is no guarantee of future results. There can be no assurance that the Strategy will continue to hold these positions or that weightings do not change after the as of date stated.

THIRD QUARTER 2026 · PORTFOLIO COMMENTARY

During the third quarter of 2026, the Axiom Emerging Markets Equity Strategy declined 5.9% net of fees, compared with a 0.4% decline for the MSCI Emerging Markets Index. Following strong gains earlier in the year, the strategy was up 29.1% net of fees year-to-date versus 23.4% for the benchmark, with continued strong absolute and relative performance over one year, three years and since inception. The quarter's decline was concentrated in July, followed by a partial recovery over August and September. Higher energy prices, persistent inflation and rising interest rates triggered a sharp reversal in market leadership, amplified by leveraged unwinds elsewhere in the market.

Our semiconductor and industrial holdings, important drivers of earlier gains, were particularly affected. Portfolio fundamentals continued to improve as our earnings revision measure showed quarterly upgrades of approximately 4%, compared with about 2% for the benchmark. At quarter-end, expected earnings growth over the next twelve months was 39.7%, compared with 34.1% for the benchmark. We view the market turbulence as an interruption to a strong underlying growth trajectory, with continued earnings upgrades and lower valuations suggesting attractive opportunities to add exposure.

From a sector perspective, healthcare and consumer staples contributed positively to relative performance. Industrials, information technology and financials were the largest detractors. Financials contributed positively to absolute returns but lagged the benchmark. Our energy underweight also detracted. We remain cautious on energy prices as adaptations to trade routes have restored Gulf oil exports to approximately 90% of prewar levels, demonstrating supply resilience. De-escalation could further ease disruptions and lower the geopolitical premium in oil prices, benefiting consumers and corporate margins.

From a country perspective, Peru, Brazil and Hong Kong provided the largest positive relative contributions. Latin America was the strongest contributing region. China, Korea and Taiwan were the largest detracting countries, while Asia ex-Japan and the emerging markets of Europe, the Middle East and Africa were the largest regional detractors.

WuXi AppTec, ASPEED Technology and Embraer were the largest stock-specific relative contributors, followed by the benefit of not owning Yageo and our position in China Construction Bank. The largest detractors were SK hynix, Samsung Electronics, Accton Technology, Contemporary Amperex Technology and Piotech. SK hynix, our largest quarterly relative detractor, saw its shares decline approximately 23% but remained a leading year-to-date contributor, with the stock up approximately 191% through quarter-end. At approximately four times forward earnings, expected earnings growth of 60% underscores the opportunity. Concerns that multiyear customer agreements could temper near-term pricing upside weighed on sentiment, although these commitments improve demand visibility. June-end net cash of approximately ₩69 trillion and an announced ₩40 trillion share repurchase and cancellation program support investment capacity and shareholder returns.

We continue to find what we believe are attractive opportunities to broaden the portfolio's sources of growth. While retaining core exposures to the AI investment cycle, we reallocated some gains to healthcare, consumer and financial businesses. We increased positions in WuXi AppTec and Hansoh Pharmaceutical and initiated Allegro, broadening exposure to drug development and consumer commerce. We also increased Embraer and ICICI Bank and added Grupo Cibest, diversifying growth across commercial aviation and financial services. These allocations enhance portfolio resilience while retaining meaningful exposure to semiconductor and computing demand.

Underlying fundamentals continue to strengthen across our opportunity set. Falling inference costs, improving capabilities and increasingly intensive agentic applications are expanding AI adoption and computing demand. Accelerating demand could shorten investment payback periods relative to current expectations, while greater emphasis on incremental cash generation strengthens financial discipline. Healthcare's positive contribution, led by WuXi AppTec, illustrates the opportunity beyond AI infrastructure. Drug development, commercial aviation and financial services provide additional sources of growth. We believe our Dynamic Growth approach identifies fundamental acceleration that can exceed market expectations, reinforcing conviction in existing holdings while uncovering new opportunities. Potential de-escalation and reduced uncertainty following the U.S. midterms could provide additional support.

We see the current share-price resets as an attractive opportunity for thoughtful investors to add exposure as underlying fundamental strength continues to compound. Portfolio forward P/E moved from 13.2 times to 10.6 times, well below its five-year average of 15.1 times. A portfolio PEG ratio of approximately 0.27, compared with 0.28 for the benchmark, underscores attractive valuations relative to expected growth across emerging markets. Continued earnings upgrades, expected earnings growth above the benchmark, returns on equity above 26% and an aggregate net cash position provide a compelling foundation for future growth and returns.

CLIENT PARTNERSHIP CONTACTS

Lindsay Chamberlain
Managing Director
203.422.8039
lchamberlain@axiom-investors.com

Steve Hanson
Director of Client Partnerships
203.422.8085
shanson@axiom-investors.com

Siobhan Kranz, CFA
Director of Client Partnerships
203.422.8044
skranz@axiom-investors.com

Greg Schneider
Director of Client Partnerships
203.422.8038
gschneider@axiom-investors.com

Rachel Callahan
Client Partnerships
203.422.8043
rcallahan@axiom-investors.com

Stephanie Keith
Client Partnerships
203.422.8062
skeith@axiom-investors.com

Andrew Lothian
Client Partnerships
203.422.8093
alothian@axiom-investors.com

Investor Services
203.422.8000
InvestorServices@axiom-investors.com

The information presented is not definitive investment advice, should not be relied on as such, and should not be viewed as a recommendation by Axiom. The securities presented are not representative of all of the securities purchased, sold or held for advisory clients, and it should not be assumed that investment in the securities identified was or will be profitable.

GIPS® COMPOSITE REPORT

Emerging Markets Equity Composite

YEAR	GROSS %	NET %	BENCH %	# ACCTS	MKT VAL $M	FIRM $M	% FIRM	DISP. %	COMP 3Y STD	BENCH 3Y STD
YTD '26	29.96	29.05	23.38	18	4,450.0	33,240.1	13.39	N/A	20.52	17.00
2025	26.99	25.80	33.57	18	4,380.2	27,573.2	15.89	0.30	13.14	13.41
2024	16.27	15.17	7.50	19	4,686.5	24,180.9	19.38	1.25	16.20	17.50
2023	6.19	5.18	9.83	18	4,817.0	19,915.6	24.19	0.45	16.28	17.14
2022	−29.96	−30.65	−20.09	19	5,691.5	16,580.9	34.33	0.23	20.17	20.26
2021	−3.22	−4.15	−2.54	17	7,526.5	18,639.7	40.38	0.26	18.49	18.33
2020	31.22	29.99	18.31	17	7,342.6	18,535.9	39.61	0.53	19.80	19.60
2019	25.98	24.79	18.42	18	6,180.6	13,458.1	45.93	0.31	14.46	14.17
2018	−15.76	−16.59	−14.58	18	4,541.1	9,729.2	46.67	0.50	14.76	14.60
2017	42.57	41.21	37.28	21	6,210.6	12,116.0	51.26	0.71	15.07	15.35
2016	9.30	8.21	11.19	16	3,170.0	9,671.6	32.78	0.17	15.55	16.07

Fee schedule: First $25 million: 1.00%; next $75 million: 0.90%; next $25 million: 0.80%; next $50 million: 0.70%; Balance: 0.60%.

FOOTNOTES & DISCLOSURES

Firm Compliance Statement: Axiom Investors LLC (the "Firm") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. Axiom has been independently verified for the period September 1, 1998 to September 30, 2026. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm's policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. The Axiom Emerging Markets Equity composite has had a performance examination for the periods August 1, 2007 to September 30, 2026. The verification and performance examination reports are available upon request.

Definition of the Firm: The firm is currently defined for GIPS purposes as Axiom Investors, LLC (the "Firm") is a registered investment advisor under the Investment Advisers Act of 1940.

Policies: Policies for valuing investments, calculating performance, and preparing GIPS Reports are available upon request. Past performance does not predict or guarantee future results.

Composite Description: The Emerging Markets Equity strategy (the "Composite") is designed for investors who seek to invest in a broadly diversified portfolio of emerging market equities. Portfolios are invested in the full range of global emerging markets. Currencies may be actively managed to reduce portfolio volatility. The Composite represents the performance of all institutional emerging markets style fee-paying, discretionary equity accounts, regardless of asset size and comingled fund(s). The Composite was initiated and created in August 2007. A list of composite descriptions, a list of limited distribution pooled fund descriptions, a list of broad distribution pooled funds and performance results are available upon request.

Benchmark Description: The benchmark is the MSCI Emerging Markets index, which is designed to measure the equity market performance in the global emerging markets. The benchmark is calculated on a total return basis with net dividends reinvested, after the deduction of withholding taxes and is free float-adjusted market cap weighted and unmanaged. FX is based off London 4 P.M. close.

Significant Cash Flow Policy: Accounts with a cash flow greater than 20% of the portfolio market value are excluded for the month.

Reporting Currency: Valuations are computed and performance is reported in U.S. dollars. FX is based off NY 4 P.M. close.

Fees: Gross of fees returns are presented before management and custodial fees but after all trading expenses. Net of fees returns are calculated by deducting the highest fee from the monthly gross composite return which is expressed above in the stated fee schedule. Returns include the reinvestment of income. Performance is calculated net of withholding taxes on dividends. The fee schedule for the Axiom Emerging Markets Equity Fund, which is included in the Emerging Markets Equity Composite is listed above. The total expense ratio as of December 31, 2025 was 0.22%. The Axiom Emerging Markets Trust CIT, which is also included in the composite has an all-in fee (management fees & expenses) of 0.78%.

Internal Dispersion: Internal dispersion is calculated using the asset-weighted standard deviation of annual gross returns of those portfolios that were in the composite for the entire year. If 5 or less accounts, N/A is shown.

Annualized Standard Deviation: The three-year annualized standard deviation measures the variability of the composite gross returns and the benchmark returns over the preceding 36-month period.

Batting Average: The number of periods that the portfolio outperforms (or matches) the benchmark divided by the total number of periods.

Tracking Error: The active risk of the portfolio. It determines the standard deviation of the excess returns between the portfolio and the benchmark. It is calculated by creating a new return series of the excess returns and then calculating the population standard deviation of that return series.

Information Ratio: A measure of consistency in excess return. The annualized excess return over a benchmark divided by the annualized standard deviation (population) of excess return.

GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.

This may contain forward-looking statements within the meaning of the federal securities laws. Actual results could and likely will differ, sometimes materially, from those projected or anticipated. We are not undertaking any obligation to update or revise any forward looking statements whether as a result of new information, future events or otherwise. You should not take any statements regarding past trends as a representation that trends or activities will continue in the future. Accordingly, you should not put undue reliance on these statements.

Axiom's standard policy is to use the MSCI country for country reporting purposes. There will be instances where the majority of a company's earnings and/or assets are located in a country within the strategy guideline, while the country of incorporation may be located elsewhere.

The information contained herein represents neither an offer to sell nor a solicitation of an offer to buy any securities or investment service. This strategy will only be offered through appropriate documents, copies of which may be obtained upon request from InvestorServices@axiom-investors.com. Offers will not be made in any jurisdiction in which the making of an offer or the acceptance thereof would not be in compliance with the laws of such jurisdiction. Investors should read applicable materials carefully before making a decision to invest.

Risks of investing in the strategy

Potential loss of investment: No guarantee or representation is made that the investment program used by Axiom will be successful. The strategy represents a speculative investment and involves a high degree of risk. An investment in the strategy should be discretionary capital set aside strictly for speculative purposes. Investors must have the financial ability, sophistication/experience and willingness to bear the risks of an investment in the strategy. An investment in the strategy is not suitable for all investors. An investor could lose all or a substantial portion of his/her/its investment. Only qualified eligible investors may invest in the strategy. Because of the nature of the trading activities, the results of the strategy's operations may be volatile from month to month and from period to period. Accordingly, investors should understand that past performance is not indicative of future results.

Fees and expenses: The strategy may be subject to substantial charges for management, advisory and brokerage fees. It may be necessary for those accounts that are subject to these charges to make substantial trading profits to avoid depletion or exhaustion of their assets.

Reliance on key persons: The strategy's manager or advisor has total trading authority over the strategy and may be subject to various conflicts of interest. The death, disability or departure of the manager or advisor may have a material effect on the strategy.

Counterparty and bankruptcy risk: Although Axiom will attempt to limit its transactions to counterparties which are established, well-capitalized and creditworthy, the strategy will be subject to the risk of the inability of counterparties to perform with respect to transactions, whether due to insolvency, bankruptcy or other causes, which could subject the strategy to substantial losses.

Volatile markets: Market prices are difficult to predict and are influenced by many factors, including: changes in interest rates, weather conditions, government intervention and changes in national and international political and economic events.

The above summary is not a complete list of the risks, tax considerations and other important disclosures relating to Axiom products or services. Prospective clients should read all disclosure documents provided by Axiom relating to its products or services before engaging Axiom's advisory services.

The information herein is only current as of the date indicated, and may be superseded by subsequent market events or for other reasons.

The Axiom Investors Collective Investment Trust is a trust for the collective investment of assets of participating tax-qualified pension and profit sharing plans and related trusts, and governmental plans as more fully described in the Declaration of Trust. The Axiom Investors Trust is managed by SEI Trust Company, the trustee, based on the investment advice of Axiom Investors, the investment adviser to the trust. As a bank collective trust, the Axiom Investors Trust is exempt from registration as an investment company.